Welcome to the official InxMed website

EN CN



CONQUERING TREATMENT RESISTANCE OF TUMORS

We dedicate on developing innovative therapies targeting tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment resistance





OUR SCIENCE

Priming tumor microenvironment with regimen，killing cancer cells and consolidating treatment via specified therapy

Learn More

R&D PIPELINE

xin

Time of issue:2023-02-21 16:41:00

Asset	Modality / Target	Regimen	Indication
IN10018 Small molecular FAK inhibitor		+ PLD	PROC (double-blind, placebo controlled, randomized study)
		+ MEKi ± IO	IO-failed NRAS melanoma Uveal melanoma
		+ PLD ± IO	PROC, TNBC, HNSCC
		+ chemotherapy + IO	IO-failed NSCLC (randomized study)
		+ chemotherapy + IO bispecific	Pancreatic cancer
		+ KRAS^G12C inhibitor	KRAS^G12CCRC and NSCLC
		+3rd EGFR inhibitor	EGFR mutant NSCLC
OMTX705	ADC Targeting FAP	Mono / Combo	Solid Tumor
INES103	Antibody Target undisclosed	Combo	Solid Tumor
IN30718	ADC Target undisclosed	Mono	Solid Tumor
IN30728	ADC Target undisclosed	Mono	Solid Tumor
IN20019	Small molecular Target undisclosed	Mono	Solid Tumor

LATEST NEWS

Press Release

2023-08-30

InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC

Nanjing, China, Aug 30, 2023 InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approval from China National Medical Products Administration (NMPA) recently.

2022-10-18

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct 18, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), alone or in combination with cobimetinib (Cobi, an approved mitogen-activated protein kinase [MEK] inhibitor from Roche) in patients with Uveal Melanoma (UM) and NRAS-mutant melanoma. The clinical data is being presented in the form of poster at the Society for Melanoma Research (SMR) 19th International Congress from October 17-20, 2022 (Abstract #: P-141). The released data showed that IN10018 in combination with Cobi demonstrated promising antitumor activities and acceptable safety profile in patients with metastatic melanoma. InxMed has entered into a global clinical collaboration with Roche to evaluate IN10018 in combination with Cobi before.

2022-09-08

InxMed Announces First Patient Dosed in Pivotal Phase 2 Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer

NANJING, China, Sep 8th, 2022 -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study evaluating IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC).

Media Coverage

2022-03-17

BioWorld：Inxmed raises $50M to develop cancer therapy in the US, China

Inxmed Co. Ltd. has raised $50 million in a series B round to support clinical trials of its lead candidate, IN-10018, for the treatment of multiple cancers in both the U.S. and China. Inxmed plans to use the funds to invest in trials of IN-10018, bring more stroma-targeting candidates into clinic trials, and improve the firm’s R&D capabilities.

2019-06-20

Dialogue | interview with Dr. Wang Zaiqi, chairman of the Organizing Committee of the 5th dia China Pharmaceutical R & D Innovation Conference in 2009

In June 2019, New England magazine published the major research achievement of Tu youyou's team - "artemisinin resistance" treatment response plan. This is an important achievement of China in the field of global drug R & D. Benchmarking international, China's R & D of innovative drugs has attracted worldwide attention.

2019-07-29

Freehand character Wang Zaiqi: research and development of individualized therapeutic drugs with global influence

Dr. Wang Zaiqi will attend the global clinical research and development failure and success case analysis, the 96th activity of the same freehand brushwork forum for the third time, and make a special report - "the experience of using anti-PD-1 combined chemotherapy drugs in gastric cancer chemotherapy - excellent early trial data and disappointing phase 3 results. What have we learned?"

We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world

QUICK LINKS

CONTACT US

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

MESSAGE

   